Multimodal endpoints advisory
Match modalities to clinically relevant, scientifically valid, commercially viable, and regulatory-accepted endpoints within the appropriate context of use.
Clinical development services
Expertise in electrophysiology, operational efficiency, and strategic foresight.
Allowing Biotech, Pharma, and MedTech to deliver effective treatment options to patients by enabling the adoption of meaningful endpoints in CNS trials.
Wedo it alone
One size doesn’t fit all, that’s why we’ve created a Curated Network of Solutions, allowing us to purposefully combine best-matched analysis, hardware, and wearable Digital Health Tech solutions via one platform - the CNS platform.
Holistic service
The building blocks of our bespoke service
Digital Health Technology partner selection
Select the appropriate data acquisition and analytics partners from our Curated Network of Solutions.
Data acquisition, aggregation & analysis
Acquire, aggregate, and analyze multi-modal data on our CNS platform with our bespoke solutions; from supporting on-site and at-home acquisitions to unique hybrid analysis efficiently combining automated analysis and expert reading.
Multimodal insight & endpoint validation
Discover novel and validate existing CNS endpoints to enhance the medical effectiveness of your clinical development through multimodal insights, starting from electrophysiology.
Interpretation & result reporting
Leverage our deep technical and clinical knowledge to translate data insights into an actionable clinical development strategy to increase your probability of success.
Curated Solutions
Selecting the right solution for your context of use
Designed to offer Biotech, Pharma, and MedTech a range of innovative solutions tailored to meet your trial needs.
From emerging technologies to well-established solutions, our partners serve diverse purposes, ensuring you have fit-for-purpose tools at each stage of your clinical development within your context of use.
Case studies
How our services helped them
Standardized Pharmaco-EEG in Clinical Development
Pharmaco-EEG measures the direct and indirect effects of active compounds on brain activity to evaluate a drug's pharmacodynamic (PD) and pharmacokinetic (PK) properties, its CNS penetration, and its potential therapeutic or toxic effects. By employing standardized methodologies, pharmaco-EEG can serve as a translational biomarker, bridging preclinical research and clinical drug development and aiding in the evaluation of CNS-active compounds in humans.
